Talphera Operating Expenses 2010-2025 | TLPH

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Talphera operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Talphera operating expenses from 2010 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$76.6B
Zoetis (ZTS)	$69B
Takeda Pharmaceutical (TAK)	$46.7B
Daiichi Sankyo, - (DSNKY)	$41.7B
BeOne Medicines - (ONC)	$27.4B
Sandoz Group AG (SDZNY)	$24.6B
Summit Therapeutics (SMMT)	$18.6B
Merck (MKKGY)	$17.2B
Shionogi (SGIOY)	$14.2B
United Therapeutics (UTHR)	$13.3B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.3B
Stevanato Group S.p.A (STVN)	$7.6B
Corcept Therapeutics (CORT)	$7.6B
Madrigal Pharmaceuticals (MDGL)	$7B
Grifols, S.A (GRFS)	$6.7B
Ionis Pharmaceuticals (IONS)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.1B
Soleno Therapeutics (SLNO)	$4.1B
Crinetics Pharmaceuticals (CRNX)	$3B
Hypermarcas (HYPMY)	$3B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$1.9B
BioCryst Pharmaceuticals (BCRX)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.7B